Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Bladder and Ureter Cancer Drug Development Pipeline Review 2017

 



(PharmaNewsWire.Com, March 07, 2018 ) This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

FREE | Request Sample Copy is Available at http://www.reportsweb.com/inquiry&RW00011464444/sample

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. This pipeline is far smaller; there are a total of nine products in development for this indication, by six companies and two academic institutions.

Scope
-Which companies are the most active within each pipeline-
-Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication-
-To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
-What are the most important R&D milestones and data publications to have happened in this disease area-

Reasons to buy
-Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
-Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
-Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
-Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Complete Report is Available at http://www.reportsweb.com/bladder-and-ureter-cancer-drug-development-pipeline-review-2017

Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Bladder and Ureter Cancer Report Coverage 9
2.2 Ureter Cancer-Overview 9
2.3 Bladder Cancer-Overview 9
3 Therapeutics Development 10
3.1 Ureter Cancer 10
3.2 Bladder Cancer 14
4 Therapeutics Assessment 34
4.1 Ureter Cancer 34
4.2 Bladder Cancer 41
5 Companies Involved in Therapeutics Development 58
5.1 Ureter Cancer 58
5.2 Bladder Cancer 61
6 Dormant Projects 125
6.1 Bladder Cancer 125
7 Discontinued Products 131
7.1 Bladder Cancer 131
8 Product Development Milestones 133
8.1 Ureter Cancer 133
8.2 Bladder Cancer 135
9 Appendix 149
9.1 Methodology 149
9.2 Coverage 149
9.3 Secondary Research 149
9.4 Primary Research 149
9.5 Expert Panel Validation 149
9.6 Contact Us 150
9.7 Disclaimer 150

ReportsWeb.com

Rajat Sahni

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC